Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
MEDROXYPROGESTERONE ACETATE
Pharmacia Ireland
2.5 Milligram
Tablets
1998-10-27
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Provera Tablets 2.5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg medroxyprogesterone acetate. Excipients: Lactose monohydrate 84.0mg, sucrose 1.375mg, sunset yellow (E110) 0.019mg For a full list of excipients, _see section 6.1._ 3 PHARMACEUTICAL FORM Tablets Orange, round, convex tablets scored on one side and marked ‘U64’ on the other one. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Progestogen. Indicated for dysfunctional (anovulatory) uterine bleeding where progesterone deficiency exists, secondary amenorrhoea, and mild to moderate endometriosis. Also indicated for use in the menopause to oppose the endometrial effects of oestrogen in post-menopausal women being treated with oestrogen. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral use. Use of combined oestrogen/progestin therapy in postmenopausal women should be limited to the shortest duration consistent with treatment goals and risks for the individual woman, and should be periodically evaluated. _(See Section 4.4_ _Special Warnings and Special Precautions for Use)._ _Adults:_ _Dysfunctional (anovulatory) uterine bleeding: _2.5 - 10 mg daily for 5 - 10 days commencing on the assumed or calculated 16 th - 21 st day of the cycle. Treatment should be given for two consecutive cycles. When bleeding occurs from a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate (MPA) in doses of 5 - 10 mg for 10 days. _Secondary amenorrhoea: _2.5 to 10 mg daily for 5 to 10 days commencing on the assumed or calculated 16 th - 21 st day of the cycle Read the complete document